DOI QR코드

DOI QR Code

Metformin Down-regulates Endometrial Carcinoma Cell Secretion of IGF-1 and Expression of IGF-1R

  • Zhang, Yu (Department of Gynecology The Third Affiliated Hospital of Sun Yat-Sen University) ;
  • Li, Meng-Xiong (Department of Gynecology The Third Affiliated Hospital of Sun Yat-Sen University) ;
  • Wang, Huan (Department of Gynecology The Third Affiliated Hospital of Sun Yat-Sen University) ;
  • Zeng, Zheng (Department of Gynecology The Third Affiliated Hospital of Sun Yat-Sen University) ;
  • Li, Xiao-Mao (Department of Gynecology The Third Affiliated Hospital of Sun Yat-Sen University)
  • Published : 2015.02.04

Abstract

As metformin can inhibit endometrial carcinoma (EC) cell growth and the insulin growth factor (IGF) system is active in EC, the question of whether it can regulate endometrial carcinoma cell secretion of IGF-1 or expression of IGF-1 receptor (IGF-1R) is of interest. In this study, serum IGF-1 levels in EC patients were found to be comparable with that in the non EC patients (p>0.05). However, the IGF-1 level in the medium of cultured cells after treatment with metformin was decreased (p<0.05). IGF-1R was highly expressed in human endometrial carcinoma paraffin sections, but IGF-1R and phosphor-protein kinase B/protein kinase B (p-Akt/Akt) expression was down-regulated after metformin treatment (p<0.05). In summary, metformin can reduce the secretion of IGF-1 by Ishikawa and JEC EC cell lines and their expression of IGF-1R to deactivate downstream signaling involving the PI-3K/Akt pathway to inhibit endometrial carcinoma cell growth.

Keywords

Metformin;endometrial carcinoma;IGF-1, IGF-1R

Acknowledgement

Supported by : Guangdong Province Natural Science

References

  1. Barakat RR, Grisby PW, Sabbatini. Corpus: epithelial tumor (2007). In: Hoskin WJ, Perez CA, Young RC principles and practice of gynecologic oncology, 2rd. Lippincott Williams & Wilkins, Philadelphia, 919-59.
  2. Bershtein LM (2014). Endometrial cancer, estrogens and metabolic syndrome: scenario becomes more complicated. Vopr Onkol, 3, 254-62.
  3. Casamassima A, Rozengurt E (1998). Insulin-like growth factor I stimulates tyrosine phosphorylation of p130 (Cas), focal adhesion kinase, and paxillin. Role of phosphatidylinositol 3'-kinase and formation of a p130 (Cas). Crk complex. J Biol Chem, 273, 26149-56. https://doi.org/10.1074/jbc.273.40.26149
  4. Creighton CJ, Casa A, Lazard Z, et al (2008). Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis, J Clin Oncol, 25, 4078-85.
  5. Derynck R, Goeddel DV, Ullrich A, et al (1987). Synthesis of messenger RNAs for transforminggrowth factors a and b and the epidermal growth factor receptor by human tumors. Cancer Res, 47, 707-12.
  6. Eugenio M, Giuseppe L, Giuseppe V, et al (1999). Insulinlike growth factor-1 expression in normal and diseased endometrium. Int J Cancer, 80, 188-93. https://doi.org/10.1002/(SICI)1097-0215(19990118)80:2<188::AID-IJC5>3.0.CO;2-E
  7. Gunter MJ, Hoover DR, Yu H, et al (2008). A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev, 4, 921-9.
  8. Goustin AS, Leof EB, Shipley GD, et al (1986). Growth factors and cancer. Cancer Res, 46, 1015-29.
  9. Goodwin PJ, Pritchard KI, Ennis M, et al (2008). Insulinlowering effects of metformin in women with early breast cancer. Clin Breast Cancer, 8, 501-5. https://doi.org/10.3816/CBC.2008.n.060
  10. Haining RE, Schofield JP, Jones DS, et al (1991). Identification of mRNA for epidermal growth factor and transforming growth factor-alpha present in low copy number in human endometrium and decidua using reverse transcriptasepolymerase chain reaction. J Mol Endocrinol, 6, 207-14. https://doi.org/10.1677/jme.0.0060207
  11. Hirano S, Ito N, Takahashi S, et al (2004). Clinical implications of insulin-like growth factors through the presence of their binding proteins and receptors expressed in gynecological cancers. Eur J Gynaecol Oncol, 25, 187-91.
  12. Kisfalvi K, Eibl G, Sinnett-Smith J, et al (2009). Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res, 69, 6539-45. https://doi.org/10.1158/0008-5472.CAN-09-0418
  13. Lelle' RJ, Talavera F, Gretz HG, et al (1993). Epidermal growth factor receptor expression in three different human endometrial cancer cell lines. Cancer, 72, 519 -25. https://doi.org/10.1002/1097-0142(19930715)72:2<519::AID-CNCR2820720231>3.0.CO;2-#
  14. Arian ER, Pascale F, Anne TN, et al (2013). Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects.Trends in Pharmacological Sciences, 2, 126-35.
  15. Baserga R (1995). The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res, 55, 249-52.
  16. Lukanov A, Zeleniuch- Jacquotte A, Lundin E, et al (2004). Prediag no st ic level o f C- peptide, IGF- 1, IGFBP- 1, - 2 and- 3 and r isk o f endometr ial cancer. Int J Cancer, 2, 262-8.
  17. Lacey JV Jr, Potischman N, Madigan MP, et al (2004). Common genetic variation within IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev, 4, 607-12.
  18. Luo Z, Zang M, Guo W (2010). AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol, 6, 457-70. https://doi.org/10.2217/fon.09.174
  19. Liu B, Fan Z, Edgerton SM, et al (2011). Potent anti- proliferative effects of metformin on trastuzumab- resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions. Cell Cycle, 10, 2959-66. https://doi.org/10.4161/cc.10.17.16359
  20. Leone A, Di Gennaro E, Bruzzese F, et al (2014). New perspective for an old antidiabetic drug: metformin as anticancer agent. Cancer Treat Res, 159, 355-76. https://doi.org/10.1007/978-3-642-38007-5_21
  21. Liang K, Qiu S, Lu Y (2014). Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells. Cancer Biol Ther, 1, 89-98.
  22. Morrow CP, Curtin JP, Townsend DE (1993). Tumors of the endometrium, in Synopsis of Gynecologic Oncology, 4th ed., New York, NY: Churchill Livingstone, 209.
  23. Morrison KB, Tognon CE, Garnett MJ, et al (2002). ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation. Oncogene, 21, 5684-95. https://doi.org/10.1038/sj.onc.1205669
  24. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, et al (2010). Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena. Cell cycle, 9, 1057-64. https://doi.org/10.4161/cc.9.6.10994
  25. Markowska A, Pawalowska M, Filas V, et al (2014). Does Metformin affect ER, PR, IGF-1R, beta-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer? Diabetol Metab Syndr, 1, 76.
  26. Nathan DM, Buse JB, Davidson MB, et al (2009). Medical management of hyperglycemia in type 2 diabetes mellitus: A consensus algorithm for the initiation and adjustment of therapy-A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 52, 17-30. https://doi.org/10.1007/s00125-008-1157-y
  27. Nevadunsky NS, Van Arsdale A, Strickler HD, et al (2014). Metformin use and endometrial cancer survival. Gynecol Oncol, 1, 236-40.
  28. Pearl MP, Talavera F, Gretz HG, et al (1993). Mitogenic activity of growth factors in the human endometrial cancer cell lines HEC 1A and KLE. Gynecol Oncol, 49, 325-32. https://doi.org/10.1006/gyno.1993.1134
  29. Pavelic Jasminka, Radakovic Branko, Pavelic Kresimir (2007). Insulin-like growth factor -2 and its receptors (IGF-1R and IGF-2R / mannose-6-phosphate) in endometrial adenocarcinoma. Gynecol Oncol, 105, 727-35. https://doi.org/10.1016/j.ygyno.2007.02.012
  30. Pollak M (2010). Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res, 3, 1060-5. https://doi.org/10.1158/1940-6207.CAPR-10-0175
  31. Rozengurt E, Sinnett-Smith J, Kisfalvi K (2010). Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res, 16, 2505-11. https://doi.org/10.1158/1078-0432.CCR-09-2229
  32. Sachdev D, Hartell JS, Lee AV, et al (2004). A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem, 279, 5017-24.
  33. Samani AA, Chevet E, Fallavollita L, et al (2004). Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of thetype 1 insulin-like growth factor receptor. Cancer Res, 64, 3380-5. https://doi.org/10.1158/0008-5472.CAN-03-3780
  34. Shaw RJ, Lamia KA, Vasquez D, et al (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310, 1642-6. https://doi.org/10.1126/science.1120781
  35. Shu SR, Li XM, Yang YB, et al (2011). Inhibitory effect of siRNA targeting IGF-1R on endometrial carcinoma. International Immunopharmacology, 2, 244-9.
  36. Salani B, Del Rio A, Marini C, et al (2014). Metformin, cancer and glucose metabolism. Endocr Relat Cancer, 6, 461-71.
  37. Sarkissyan S, Sarkissyan M, Wu Y, et al (2014). IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion. PLoS One, 7, 103534.
  38. Torng PL, LeeYC, Huang CY, et al (2008). Insulin- like growth factor protein- 3 (IGFBP- 3) act as an invasion- metastas is suppressor in ovarian endometrial carcinoma. Oncogene, 27, 2137-47. https://doi.org/10.1038/sj.onc.1210864
  39. Weiderpass E, Brismar K, Bellocco R, et al (200\3). Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J Cancer, 9, 1697-704.
  40. Xie Y, Wang YL, Yu L, et al (2011). Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. J Steroid Biochem Molec Biol, 126, 113-20. https://doi.org/10.1016/j.jsbmb.2010.12.006
  41. Xu JN, Zeng C, Zhou Y, et al (2014). Metformin inhibits StAR expression in human endometriotic stromal cells via AMPKmediated disruption of CREB-CRTC2 complex formation. J Clin Endocrinol Metab, 8, 2795-803.
  42. Zhou J, Dsupin BA, Giudice LC, Bondy CA (1994). Insulinlike growth factor system gene expression in human endometrium during the menstrual cycle. J Clin Endocrinol Metab, 79, 1723-34.
  43. Zhou G, Myers R, Li Y, et al (2001). Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 108, 1167-74. https://doi.org/10.1172/JCI13505

Cited by

  1. Evaluation of Effects of Metformin in Primary Ovarian Cancer Cells vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6973
  2. Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines vol.26, pp.7, 2016, https://doi.org/10.1097/IGC.0000000000000761
  3. Insulin-Like Growth Factor 1/Mammalian Target of Rapamycin and AMP-Activated Protein Kinase Signaling Involved in the Effects of Metformin in the Human Endometrial Cancer vol.26, pp.9, 2016, https://doi.org/10.1097/IGC.0000000000000818
  4. Induction of apoptosis by metformin and progesterone in estrogen-induced endometrial hyperplasia in rats: involvement of the bcl-2 family proteins pp.1473-0766, 2017, https://doi.org/10.1080/09513590.2017.1409708
  5. Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia vol.50, pp.4, 2018, https://doi.org/10.1007/s11255-018-1826-9
  6. Metformin as a Therapeutic Target in Endometrial Cancers vol.8, pp.2234-943X, 2018, https://doi.org/10.3389/fonc.2018.00341